Catequentinib
First-line Treatment
Shanghai Changzheng HospitalSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the First-line Treatment cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Axitinib Hao Zeng | Phase 2 | B |
Pyrotinib Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | B |
TRASTUZUMAB Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | B |
Dc-Cik Tianjin Medical University Cancer Institute and Hospital | Phase 2 | B |
Carboplatin Sun Yat-sen University | Phase 2 | B |
View all 12 →
Same molecule, other indications
Catequentinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →